Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625175 | 0.97 | MAPT (0.35) | MAPTTRPM8PTGER4GNRHRCNR2 | |
| SCHEMBL6710720 | 0.87 | PTGER4 (0.39) | MAPTTRPM8PTGER4GNRHRCNR2 | |
| SCHEMBL6714655 | 0.85 | PTGER4 (0.38) | TRPM8PTGER4GNRHRCNR2 | |
| SCHEMBL6713167 | 0.84 | PTGER4 (0.41) | MAPTTRPM8PTGER4GNRHRCNR2 | |
| SCHEMBL7258492 | 0.84 | CNR2 (0.33) | MAPTTRPM8CNR2NTSR1MC4R | |
| SCHEMBL6715058 | 0.84 | NPC1 (0.37) | TRPM8CNR2 | |
| SCHEMBL1623250 | 0.83 | PTGER4 (0.41) | MAPTTRPM8PTGER4GNRHRCNR2 | |
| SCHEMBL1626078 | 0.81 | PTGER4 (0.34) | MAPTTRPM8PTGER4CNR2HCRTR1 | |
| SCHEMBL1625476 | 0.81 | RHEB (0.38) | MAPTTRPM8CNR2 | |
| SCHEMBL21470115 | 0.81 | AGTR2 (0.37) | MAPTPTGER4GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | KDR 2614/4885MAPT 4402/4885TRPM8 2254/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | KDR 4402/4885MAPT 3288/4885TRPM8 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.